Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

The pharmaceutical powerhouse has two drugs that disrupt the transmission of the virus, one of which has been approved for ...

Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...

Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...

BofA raised the firm’s price target on Gilead (GILD) to $126 from $116 and keeps a Buy rating on the shares. For the last several weeks, ...

Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report ...

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

One of Hulu’s first original series is coming the beginning of the end on Hulu. When does ’The Handmaid’s Tale’ return?

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), ...

Gilead Sciences Inc. closed 0.11% below its 52-week high of $112.11, which the company reached on February 25th.